Olympus 2010 Annual Report Download - page 16

Download and view the complete annual report

Please find page 16 of the 2010 Olympus annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 68

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68

14 OLYMPUS 2010
LIFE
SCIENCE
BUSINESS
REVIEW OF OPERATIONS
1.
CONFOCAL LASER
SCANNING MICROSCOPE
FLUOVIEW
FV10i
Employing newly developed
electric-powered operation
and software, the FV10i offers
users easier and quicker
manipulation. In addition,
because it is contained in one
complete housing, the FV10i
can be used anywhere and
offers cost savings thanks to
integrated functions based on
Olympus’s laser microscope
technologies.
MICRO-IMAGING
Sales in the micro-imaging (microscopes) business fell
5.1% year on year to ¥63,808 million (US$709 million). In
biological microscopes, sales of research-use products
in the FLUOVIEW confocal laser scanning microscope
series were strong in the Japanese market. On the back
of corporate capital investment restraint, however, sales
of industrial microscopes decreased in the first half of
the fiscal year under review. In addition, foreign currency
exchange rate fluctuations negatively affected the
revenue of this business.
The main products of the Life Science Business are
biological microscopes, industrial microscopes and
clinical hemanalysis systems. On August 3, 2009,
Olympus sold its diagnostic systems business to
U.S.-based Beckman Coulter, Inc.
Sales in this business fell 32.6% year on year to
¥80,100 million (US$890 million), while operating
income rose 18.1% to ¥5,620 million (US$62 million).
The revenue decline in this business is attributable
to the sale of the diagnostic systems business, which
caused sales to fall approximately ¥3,500 million, as
well as the negative impact of the strong yen, which
amounted to approximately ¥4,500 million. However,
the Company’s aggressive approach to reducing costs
resulted in increased operating income.
* For reference, sales and operating income in the fiscal year under review after the
segment reclassification amounted to ¥114,100 million and ¥8,800 million, respectively.
Domestic
Sales
Overseas
Sales
(Millions of yen)
1009
SALES
131,446
29,590
101,856
118,819
22,740
96,079 80,100
21,171
58,929
08